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Abstract 
After discovery and characterization of the adenovirus in the 1950s, this prevalent cause of the 
common cold and other usually mild diseases has been modified and utilized in biomedicine in several 
ways. To date, adenoviruses are the most frequently used vectors and therapeutic (e.g. oncolytic) 
agents with a number of beneficial features. They infect both dividing and non-dividing cells, enable 
high-level, transient protein expression, and are easy to amplify to high concentrations. As an 
important and versatile research tool, it is of essence to understand the limits and advantages that 
genetic modification of adenovirus vectors may entail. Therefore, we performed a retrospective 
analysis of adenoviral gene therapy constructs produced in the same laboratory with similar methods. 
The aim was to assess the impact of various modifications on the physical and functional titer of the 
virus.  
We found that, genome size (designed within “the 105% golden rule”), did not significantly affect 
the physical titer of the adenovirus preparations, regardless of the type of transgene (e.g. 
immunostimulatory vs other), number of engineered changes, and size of the mutated virus genome. 
One statistically significant exception was noted, however. Chimeric adenoviruses (5/3) had a slightly 
lower physical titer compared to Ad5-based viruses, although a trend for the opposite was true for 
functional titer. Thus, 5/3 chimeric viruses may in fact be appealing from the safety versus efficacy 
viewpoint. Armed viruses had lower, both functional and physical, titers than unarmed viruses, while 
five genomic modifications started to decrease functional titer. Importantly, even highly modified 
armed viruses generally had good titers compatible with clinical testing.  
In summary, this paper shows the plasticity of adenovirus for various vector, oncolytic, and armed 
oncolytic uses. These results inform future generations of adenovirus-based drugs for human use. 
This information is directly transferable to academic laboratories and the biomedical industry 
involved in vector design and production optimization. 
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Introduction 
Genetic engineering methods have enabled the modification of wild-type viruses for use as safe and 
effective gene therapy vectors for multiple diseases 1. Among the most thoroughly-characterized gene 
therapy vectors is the adenovirus, which also continues to be the most popular 2. Wild-type 
adenoviruses commonly infect the upper respiratory, gastrointestinal and urinary tracts, or the 
conjunctiva, causing mild and self-limiting disease. Occasionally, pneumonia or even encephalitis 
can occur in immunosuppressed individuals or children. Of note, rare cases of systemic dissemination 
of adenovirus demonstrate the ability of the virus to travel through blood into distant tissues, which 
has implications for therapeutic use of tumor-selective viruses 3. In this regard, it is not surprising 
that transduction of non-injected metastases has been seen in cancer patients 3-5.  
Adenovirus is a non-enveloped double-stranded DNA virus with a protein capsid 6. The capsid 
structure encloses a genome consisting of roughly 36 kilobase (kb) pairs 7. Conveniently, the virion 
structure allows insertion of complementary DNA (cDNA) elements for expression of foreign 
transgenes. In addition to immunostimulatory transgenes (e.g. cytokines and chemokines), non-
immunostimulatory transgenes (e.g. tagging proteins such as luciferase, GFP, or prodrug converting 
enzymes, and ion channels), and cDNA coding for full-length antibodies (e.g. anti-CTLA4 and anti-
HER2) can be inserted into the adenovirus genome to generate recombinant adenoviral vectors 8,9.   
For therapeutic gene transfer purposes, replication-deficient adenovirus vectors can be engineered. In 
this approach, adenoviral early genes (E1-E4, often just E1 and E3) are deleted and replaced with a 
transgene of interest 6. The inserted genes are typically placed under a constitutive promoter element, 
such as the cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter, which allow transgene 
expression in any transduced cell. For example, Advexin is an E1/E3-deleted serotype 5 adenovirus 
expressing wild-type p53 under CMV 10. A similar virus, Gendicine, has been approved for routine 
use in China.  
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In another embodiment of the vector concept, adenoviruses coding for immunostimulatory cytokines 
have been constructed and used clinically for various cancer types; AdCAIL-2 and TG1024 are both 
interleukin-2 (IL-2) –encoding non-replicating vectors explored in the treatment of melanoma  11,12. 
Also several other cytokines have been inserted, including tumor necrosis factor alpha (TNFa)13, 
interferon beta (IFNb) 14, and interferon gamma (IFNg) 15. Prodrug converting enzymes have also 
been a popular approach, such as rAd/CPG2(Q3)-Thy1 coding for GPI anchored, prodrug converting 
carboxypeptidase G2 16. Several vector approaches have been promising enough to make it to 
randomized phase 3 testing, but adenoviral virotherapy agents for cancer treatment have not been 
approved outside of China yet 13.  
In contrast to replication-deficient viruses, replication-competent oncolytic viruses are able to go 
through their entire life cycle in a tumor but not in normal cells, culminating in cell lysis and release 
of new virions. Tumor specificity can be achieved on the level of replication with tumor-specific 
promoters or deletions transcomplemented in tumor cells (transcriptional targeting). In addition, the 
virus capsid can be modified to increase infection of tumor cells, or to overcome lack of receptors 
that are down-regulated in advanced cancers (transductional targeting) 6,17,18.  
In the former approach, tumor tissue –active promoters, such as human telomerase reverse 
transcriptase (hTERT), carcinoembryonic antigen (CEA), cyclooxygenase (Cox-2), and E2F, have 
been used in oncolytic adenovirus constructs 19-22. Deletions of E1b55k or E1A constant region 2 
have been employed to restrict the virus replication to cells defective in the p14ARF/p53 or p16/Rb 
pathways, respectively. Oncorine, an oncolytic adenovirus approved for the treatment of head and 
neck cancer in China, is an example of the former type of deletion mutant. Of note, it is logical to 
combine the benefits of vectored transgene delivery with the oncolytic platform capable of local 
amplification and systemic dissemination to metastases 4.  
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In addition to transcriptional targeting, the adenovirus fiber protein can be modified to feature either 
synthetic elements such as RGD-4C or structures from different serotypes. Often the goal is to avoid 
reliance on the Ad5 receptor (coxsackie adenovirus receptor CAR), which is known to be almost 
universally down-regulated in advanced metastatic tumors due to its role in cellular adhesion 23. To 
solve this issue, several adenovirus variations have been explored, such as Ad5/7 24, Ad5/11 25, 
Ad5/35 26 and Ad3/Ad11p 27 . The clinically most studied chimera, however, is the 5/3 structure 
which features the knob of serotype 3 in an otherwise Ad5 virion 22,23,28,29. Again, there is no reason 
to avoid combining the benefits of transductional targeting with the armed oncolytic platform 30.  
Heretofore, a systematic analysis of the effects of adenovirus modifications (i.e. capsid structure, 
transgene type, and overall number of changes) on viral vector yield has not been performed. We 
gathered physical and functional titer data of circa 50 different adenoviral gene therapy constructs 
produced in the Cancer Gene Therapy Group (CGTG) at the University of Helsinki between 2002 
and 2018 to assess the impact of various modifications on virus titers. Additionally, since it has been 
suggested that the amount of DNA that can be packaged into adenovirus virions is limited 31,32, we 
performed correlation analysis to evaluate the effect of genome size on virus titers.  
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Materials and Methods 
Adenoviruses 
Adenovirus construction and production is described in detail in the sources found in Table 1. 
Typically, non-replicative viruses were constructed by insertion of a transgene into a cloning plasmid, 
which was then co-transfected with a “rescue plasmid” (containing the rest of the virus genome) into 
bacteria featuring the requisite eukaryotic recombination enzymes. Linearized plasmid was then 
propagated in e.g. HEK293 cells, which provide the E1 region in trans 23. Many replication competent 
(oncolytic) chimeric adenoviruses were constructed by an adapted BAC- recombineering method 33-
35, and propagated in non-transcomplementing A549 cells to avoid the risk of back-recombination 
generating a modified but non-tumor selective virus. Produced virions were collected from cells 
showing cytopathic effect by trypsin detaching or scraping, centrifugation, and repeated freeze-thaw 
cycles. Downstream purification employed two consecutive cesium chloride density centrifugations 
followed by dialysis to remove cesium chloride.  
Physical titer (virus particles, VP) was assessed spectrophotometrically (OD260 reading). Functional 
titering was done with Tissue Culture Infectious Dose (TCID50) assay in HEK293 or A549 cells, 
depending on virus type. TCID50 titers were converted into a more conventional plaque forming units 
(PFU) titer using a formula 18,36. VP/PFU ratios (physical to functional titer) were calculated by 
dividing VP titer with PFU titer. 
Statistical analyses 
All virus constructs included in statistical analyses are listed in Table 1. All statistical analyses, 
Kruskal-Wallis and Spearman correlation were performed using GraphPad Prism 7 (GraphPad 
Software Inc., San Diego, CA, USA). 
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Results 
Chimeric 5/3 adenoviruses have moderately lower physical, but not functional, titers compared 
with fully serotype 5 viruses 
Viruses with fully serotype 5 capsid structure had the highest VP titers with an arithmetic mean of 
4.2 x 1012 VP/ml and median of 2.3 x 1012 VP/ml (n = 30 virus preparations) (Figure 1a, Figure 1c). 
Chimeric 5/3 viruses had lower titers with a mean of 2.4 x 1012 VP/ml and median of 1.1 x1012 (n = 
88), and the difference to serotype 5 viruses was statistically significant (p = 0.0412, Kruskal-
Wallis).Viruses with other capsid modifications (RGD, pk7, pk21, RGD + pk7) had a similar trend 
for moderately lower VP titers (mean value 2.4 x 1012 VP/ml, median =1,9 x 1012, n = 6, not 
statistically significant; note smaller n) versus fully Ad5.  
Functional titers were not significantly different between fully Ad5, chimeric 5/3, and other capsid-
modified adenoviruses. Ad5 mean PFU titer was 1.1 x 1011 PFU/ml, 5/3 chimeric virus mean was 
more than twice as high (2.5 x 1011 PFU/ml), while the mean of the other capsid modification group 
was lower (4.4 x 1010 PFU/ml). The respective medians were: serotype 5 = 9.0 x 1010 PFU/ml, 
chimeric 5/3 = 4.0 x 1010 PFU/ml, other modifications = 4.8 x 1010 PFU/ml) (Figure 1b, Figure 1d).  
Ratios of physical to functional titer were not significantly different between groups (Figure 1e). The 
ratio was 37.6 for Ad5 and 35.2 for Ad5/3. Because some clear outliers were identified, medians were 
used for ratio calculations. Regarding outliers, Ad5/3lucS*37 with shaft mutations, had ratios ranging 
from 11483 to 79556, suggesting that this capsid configuration (or other properties of the virion) did 
interfere with virus production and function. (Figure 1e).  
 
 
Transgene type significantly affects functional virus titers  
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Comparison of physical VP titers of viruses with different transgene types did not reveal significant 
differences (Kruskal-Wallis) (Figure 2a). It is noteworthy, however, that the functional titer of virus 
groups with immunostimulatory (p=0.0054), non-immunostimulatory transgenes (p=0.0403) and 
antibody (p=0.0131) transgenes were significantly lower compared with the control group of viruses 
with no added transgenes (Figure 2b). Comparison of transgene groups revealed significantly lower 
ratios for the immunostimulatory group (p= 0.0016) and antibody groups (p=0.027) compared with 
the group with no transgenes (Figure 2c). 
 
Number of modifications affects virus functionality 
Viruses were grouped according to the number of functionally relevant, engineered, modifications. 
Kruskall-Wallis analysis did not indicate statistically significant differences between the number of 
modifications and physical/functional titers, or the ratios between physical and functional titers when 
fewer than 5 modifications were done. However, five  genetic modifications caused a significant drop 
in the physical and functional titers (p= 0.139 and p=0.002 respectively) (Figure 3 and 
Supplementary Table 1).  
 
Genome size does not correlate with physical or functional virus titer  
We performed Spearman correlation analysis comparing functional titers with genome sizes. Wild-
type adenovirus serotype 5 (Ad300wt strain purchased from ATCC) served as 100% reference value. 
When genome size was plotted against physical titer, we observed no correlation between the two 
factors (r = 0.04) (Figure 4a). Similar results, indicating a lack of correlation, were observed with 
functional titer (r = -0.06) (Figure 4b) and VP/PFU ratio (r = -0.03) (Figure 4c). Of note, we have 
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not attempted to make viruses whose genome size would be smaller than 98% or larger than 105% of 
the wild-type genome, and it seems unwise to extrapolate our findings beyond these limits.  
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Discussion  
The construction and production of biological therapeutic agents for human use is a heavily regulated 
field with a high demand of accuracy in order to provide safety and reliable drugs. Importantly, as 
adenoviruses are being utilized for several clinical and preclinical purposes, it is of essence to 
understand the effects of man-made modifications to the packaging ability of the virus. One of the 
main reasons for conducting modifications to adenovirus vectors relates to the concern regarding pre-
existing immunity against the vector and subsequent vector-depleting immune response and 
toxicity38.  
The adenovirus capsid consists mainly of three components (fiber, penton and hexon proteins), which 
are available for neutralizing antibodies. Of these, the fiber proteins alone do not seem to function as 
major targets for neutralizing antibodies, since the hexon proteins have been shown to be important 
immunoneutralizing targets as well 39. Therefore, it is expected that while chimerism and other 
modifications to the fiber allow a degree of escape from pre-existing antibodies 40, they do not 
dramatically affect the immunogenicity of the viruses. Thus, over time antibodies will develop also 
against modified capsids. Of note, with increased understanding of selecting the right vector for each 
purpose, adenovirus has been very safe in the context of cancer therapy 39,41-43. Immunogenicity is an 
important tool when inducing anti-tumor immunity while it might be a caveat when treating 
hereditary disease, for example.  
In cancer therapy, the antiviral immune response is harnessed as a positive, immune system 
activating, tumor depleting force in the battle against difficult-to-treat tumors. In this regard, some 
early studies identified key issues regarding vector design, such as the association of genome size and 
virion stability 7,31,32. They concluded that adenovirus vectors are unstable at sizes over 39 kb, which 
is roughly 105% of the wild-type adenovirus genome size. This result has subsequently been applied 
as a golden standard when adenovirus vectors have been developed and designed.  
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Interestingly, however, even though many types of oncolytic and vector adenoviruses have been 
constructed, it is not known how modification type, the number of engineered modifications, capsid 
type, or replication competence affect stability and packaging of the virus.  Lack of understanding of 
these issues is a major caveat in the field, since on one hand, it is easy to attempt to construct almost 
any type of virus, but on the other, many of the modifications that can be envisioned, might easily 
affect virus assembly.  
For example, capsid is one of the key determinants in virion stability, so any changes to it could 
reduce titers. Moreover, transgenes added to the virus genome could potentially affect producer cells. 
Subsequently, it would not be surprising if the number of modification would eventually decrease the 
ability of the virus to replicate. In the course of evolution, each of the 57 adenovirus serotypes 
discovered to date, have been optimized for stability and replication. Thus, man made, engineered 
changes could result in decrease in these attributes. The adenovirus genome is read in both directions, 
and most of the DNA is coding sequence, indicating that any change can have unexpected changes in 
other adenovirus proteins.   
Therefore, we analyzed the effect of modifications in vectors used and/or made in CGTG at the 
University of Helsinki. Several modifications to the adenovirus fiber and/or knob have been 
employed, altering the specificity and efficacy of infection.  In this study, we found that virions with 
chimeric 5/3 fiber modifications produced a slightly but statistically significantly lower physical titer 
compared with virus preparations produced with unmodified Ad5 knob and shaft domains. In 
contrast, mean functional titers seemed higher with chimeric viruses. This is in accord with previous 
findings indicating that chimeric viruses result in a higher rate of oncolysis, virus DNA to nucleus 
transportation, and more efficient replication efficacy compared with control viruses 44.  
Efficacy, however, is a multifactorial endpoint influenced not only by virus replication and lysis of 
cells, but also infection dynamics related to expression of the relevant receptors. There is much data 
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indicating that the receptors for Ad5/3, such as desmoglein 2, are expressed to higher degree on tumor 
cells than the Ad5 receptor CAR 17,44,45. Additionally, some data indicate that 5/3 chimerism also 
enhances replication efficiency 44, thus other than chimeric modifications made to the analyzed virus 
preparations seem to hamper the previously noted enhanced virion production. 
Importantly, a lower physical to functional particle ratio may be advantageous for human use. 
Adverse events are known to be associated with physical titer, while efficacy is associated with 
functional titer. For these reasons, physical titering is recommended in clinical trials  as safety is even 
more important than efficacy 46.  
Of note, the titers reported here are not the result of optimization of production. Instead, in most 
academic laboratories, students, technicians, and other researchers produce viruses themselves, with 
limited optimization of the process. At CGTG, we do perform a panel of quality control assays on 
each virus batch produced, and batches not fulfilling these criteria are discarded. However, process 
development has not been the most important issue in preclinical stages and academic processes, 
since standard methods generally give good adenovirus yields. In contrast, when moving on to clinical 
trials, it is important to minimize the proportion of inactive particles (which influence adverse events 
but not efficacy), emphasizing the importance of process development in virus production. Testing 
the multiplicity of infection, cellular confluency, the cell line used, infection medium, harvest time, 
and other details can increase yield dramatically 47.  
The observed production efficacy was similar when the group of “other capsid modifications” was 
compared with wild-type-capsid virion preparations. The other capsid modifications group contains 
several different knob protein modified virions, thus, these modifications might have altered the 
stability of the virions in the production system. Although fiber protein modifications of Ad2 have 
been shown to impact the assembly of the virion 48, a negative effect of knob protein modifications 
on virion stability could be less obvious, because the knob proteins are located on the outermost parts 
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of the virion. Additionally, several studies have noted a higher infectivity of knob modified Ad5, 
which would not have been seen if the knob modified virions were very unstable 17,49. 
We hypothesized that when transgenes are inserted into the adenovirus genome, titers could be 
influenced. Transgene products are produced during virus replication, which might reduce the ability 
of the cell to produce viral proteins, assuming an overall limited production capacity. Alternatively, 
the transgene product itself might affect the host’s signaling cascades, eventually either hampering 
or – less likely - enhancing the virion production efficacy. Therefore, the transgenes in this study 
were grouped and analyzed with regard to virus titers. We found that the type of insert did not impact 
the number of produced total virions. However, the production of functional (PFU) virions was 
significantly lowered (e.g. immunostimulatory vs no transgene). Therefore, this indicates that 
transgenes can affect the host cell production thus impeding optimal production and/or folding of 
virion peptides, the correct assembly of the virion, or some other yet unidentified part of proper virus 
production. 
The effect of the number of modifications was examined in detail. No significant differences in 
physical- and functional titers between preparations of viruses with zero to four modifications was 
observed. However, the titer was significantly lowered when five modifications were made to virus 
genomes.  This might be caused by a variety of reasons. For example, several signaling sequences 
are imbedded into the genome, and the sequence in itself can function as a stabilizing entity50. 
Alternatively or in addition, some other yet unknown functions of the sequence might have been 
disturbed unknowingly while modifying the genome. 
As previous studies by Kennedy and Parks had shown that genome size exceeding 105 % is 
undesirable7, all virus preparations made in this study were constructed within this rule. Additionally, 
it has been suggested that smaller genome size correlates with poorer heat stability of adenovirus 
virions and if crucial virion proteins are deleted, helper viruses are needed. Thus, this indicates that 
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deleting too much can be counterproductive. However, in the study conducted by Kennedy and Parks, 
the virions also contained additional modifications, which might have affected results7. However, it 
is maybe not so interesting to make smaller viruses, because often the aim is to use the virus to deliver 
a payload, which requires adding something to the virus.  
Thus, it was of interest to see how sensitive virion production was to size changes within the 105% 
“golden rule”. This analysis revealed that size of the studied virus genomes did not affect the physical 
or functional virus titers. When adenoviruses are assembled, the electrostatic interactions between 
DNA and the capsid proteins are neutralized by the basic adenoviral proteins VII, V, and µ, thus 
probably contributing to the noted flexibility of the adenovirus virions51.  
With replication-competent viruses, the input titer is just one variable. With each tumor cell producing 
tens of thousands of new virions, titer may not be the critical determinant of overall efficacy. Instead, 
when designing viruses for cancer treatment, cellular, intratumoral, and anti-viral issues may be more 
relevant. Also, intratumoral complexities such as extracellular matrix, hyperbaric, necrotic, hypoxic, 
and acidic areas may thwart spreading of the virus 52. Of note, the production of big proteins such as 
antibodies and immunostimulatory proteins, seems to be a burden to functional virion production, 
and thus needs the attention from virologists in order to solve this issue. In conclusion, the data 
collected in this study reveals that adenovirus can be modified quite flexibly without clinically 
relevant loss of functional titer. 
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